

# Insurer Goes High-Deductible—for Its Employees

BY M.R. TRASKA  
Contributing Writer

United Healthcare still sells managed care plans to employers, but not to its workers.

Starting this month, all United Healthcare (UHC) employees have had just one major option for health insurance: a high-deductible plan. Employees get to choose among different high-deductible packages and are encouraged to combine those with health savings accounts (HSAs). When combined with high-deductible insurance, HSAs are used to pay out-of-pocket health expenses.

The move into high-deductible plans is a drastic departure from the kind of low out-of-pocket cost, comprehensive benefit package that was once UHC's mainstay. How can the firm reconcile this with managed care?

"They can't," said Greg Scandlen, director of the Center for Consumer Driven

**The Blue Cross and Blue Shield Association projects that by 2006, Blues plans will offer HSA-compatible products in all but one state for large employer groups.**

Health Care at the Galen Institute, Alexandria, Va. In his opinion, "these hybrid kinds of PPO-type approaches [that UHC is offering] don't really work."

High-deductible plans are not exactly new to UHC. Employees and

customers have been offered the plans for several years, and both groups have received the product enthusiastically, according to company spokesman Mark Lindsay. Mr. Lindsay declined to estimate how many employees had chosen the high-deductible option previously. He also would not elaborate on specific plan features—for example, whether UHC's plans provide first-dollar coverage for preventive visits as an incentive for patients to get such care.

The move is "a signal that United sees high-deductible HSAs as the wave of the future," said Paul Ginsburg, Ph.D., president of the Center for Studying Health System Change, Washington. He said he sees this move as strong marketing symbolism for United's customers.

Gary Claxton, director of the Health Care Marketplace Project at the Kaiser Family Foundation, Washington, called the change "consistent with a retreat from managed care."

In a survey of more than 1,900 employers released last year, the foundation found that fewer than 1% of companies offered high-deductible HSA plans, but 6% said they were very interested in offering them within 2 years, and 21% said they were somewhat likely to offer them. Of firms with 5,000 or more employees, 22% were very likely to offer the plans within 2 years, and 28% were somewhat likely to do so.

Insurers are starting to plan for those future demands. Blue Cross and Blue Shield

plans currently offer HSA-compatible coverage in 34 states for large and small employer groups and in 32 states for individuals. The Blue Cross and Blue Shield Association projects that by 2006, Blues plans will offer HSA-compatible products in all but one state for large employer groups, in 48 states for small employers, and in 44 states for individuals. Even Kaiser Foundation Health Plans, an Oakland, Calif.-based insurer whose main offering is a closed-panel HMO, confirmed that it,

too, began to offer a similar high-deductible product last year and planned to combine it with HSAs this year.

"Generally, I'm very concerned" about a significant move into high-deductible plans, said Mila Kofman of Georgetown University Health Policy Institute, Washington. "We know very little about the effects of that on people with chronic illnesses or limited incomes."

High out-of-pocket costs can discourage people with chronic diseases, such as dia-

betes, from getting preventive or maintenance care that would prevent costly intervention later.

In the longer term, the higher deductible plans could actually cost employers more than they save from lowered premiums as more acute illness is treated at later stages, employees end up sicker, and absenteeism increases, she said. "I'm not sure that making people pay more out of pocket will make the overall system more efficient." ■

The starting and maintenance dose for MOBIC is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. Higher doses of MOBIC (22.5 mg and greater) have been associated with an increased risk of serious GI events; therefore, the daily dose of MOBIC should not exceed 15 mg.

**Indications:** MOBIC is indicated for relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis.

**Contraindications:** MOBIC is contraindicated in patients with known hypersensitivity to meloxicam. It should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactoid-like reactions to NSAIDs have been reported in such patients.

#### Important NSAID risk

**information:** Patients should be informed about the signs and/or symptoms of serious GI toxicity and the steps to take if they occur. It has been demonstrated that upper GI ulcers, gross bleeding or perforation, caused by NSAIDs, appear to occur in approximately 1% of the patients treated for 3-6 months, and in about 2-4% of patients treated for one year. Serious GI bleeding can occur without warning.

Please see following pages for Brief Summary of Prescribing Information.

## MOBIC: A TREATMENT OPTION FOR OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS

- Improvement in pain, stiffness, and physical function in OA studies<sup>1</sup>
- Significant improvement in ACR20 responder rate in an RA study
- Low incidence of serious GI adverse events<sup>2</sup>
- Low incidence of hypertension and edema in OA studies<sup>3</sup>
- No sulfonamide contraindication
- Once-daily 7.5 mg and 15 mg tablets for OA and RA



**EFFICACY WITH  
BALANCED SAFETY**

[www.mobictablet.com](http://www.mobictablet.com)

References: 1. Yocum D, Fleischmann R, Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. *Arch Intern Med.* 2000;160:2947-2954. 2. Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. *Am J Med.* 2004;117:100-106. 3. Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.